You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
默沙東(MRK.US)擬百億美元收購Verona(VRNA.US) 後者盤前股價急升逾20%
美國製藥巨頭默沙東(MRK.US)周三宣布,將以約100億美元收購英國生物製藥公司Verona Pharma(VRNA.US),以強化其慢性阻塞性肺病(COPD)治療藥物的產品線。受消息刺激,Verona股價在盤前交易中急升逾20%。 根據協議,默沙東將透過旗下子公司以每股107美元的價格收購Verona的美國存託股票(ADS),較周二收市價86.86美元溢價23.2%。雙方在聯合聲明中表示,整項交易價值約為100億美元。 Verona開發的Ohtuvayre藥物於去年6月獲美國食品及藥物管理局(FDA)批准,用於成人COPD患者的維持性治療。該款創新吸入式藥物結合支氣管擴張與非類固醇消炎作用,是逾20年來首款具新機制的COPD治療方案。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account